Vimpat and Temporal memory loss for Men aged 60+ (a phase IV clinical study of FDA data)

Summary:

Temporal memory loss is found for men aged 60+ who take Vimpat (lacosamide). This study is created by eHealthMe based on reports of 1,517 men aged 60+ from the FDA, and is updated regularly. The information that eHealthMe analyzes includes:

Time on Vimpat when people have Temporal memory loss
Top conditions
Top co-used drugs
Top other side effects

On Aug, 05, 2026

1,517 men aged 60+ reported to have side effects when taking Vimpat.
Among them, 33 people (2.18%) have Temporal memory loss

What is Vimpat?

Vimpat has active ingredients of lacosamide. It is often used in epilepsy. eHealthMe is studying from 20,832 Vimpat users. Check the latest studies of Vimpat.

What is Temporal memory loss?

Temporal memory loss (memory loss due to scarring on left temporal lobe) is found to be associated with 3,793 drugs and 4,610 conditions by eHealthMe. Check the latest studies of Temporal memory loss.

Number of reports submitted per year:

Could Vimpat cause Temporal memory loss in men aged 60+?

Time on Vimpat when people have Temporal memory loss *

Severity of Temporal memory loss

n/a

How people recovered from Temporal memory loss

n/a

Top conditions involved for these people *:

You may use this to check any potential undetected conditions.

High Blood Cholesterol: 4 people, 12.12%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 4 people, 12.12%
Partial Seizures (seizures which affect only a part of the brain at onset): 3 people, 9.09%
Pain: 2 people, 6.06%
Neuropathy Peripheral (surface nerve damage): 2 people, 6.06%
Nerve Injury: 2 people, 6.06%
Chest Pain: 1 person, 3.03%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 3.03%
Back Pain: 1 person, 3.03%
Blood Pressure Abnormal: 1 person, 3.03%

Top co-used drugs for these people *:

You may use this to check any potential interacting drugs.

Keppra: 9 people, 27.27%
Methotrexate Sodium: 4 people, 12.12%
Midazolam: 4 people, 12.12%
Cosentyx: 4 people, 12.12%
Ramipril: 4 people, 12.12%
Flonase: 3 people, 9.09%
Xarelto: 3 people, 9.09%
Vitamin D: 3 people, 9.09%
Metformin Hydrochloride: 3 people, 9.09%
Symbicort: 3 people, 9.09%

Top other side effects for these people *:

You may use this to check any potential undetected side effects.

Speech Disorder: 8 people, 24.24%
Speech Impairment (Adult) (inability to speak (adult)): 6 people, 18.18%
Cognitive Disorder (mental health disorders affects learning, memory, perception, and problem solving): 6 people, 18.18%
Fall: 5 people, 15.15%
Transient Ischaemic Attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow)): 5 people, 15.15%
Fainting (loss of consciousness and postural tone): 5 people, 15.15%
Blood Thyroid Stimulating Hormone Increased: 4 people, 12.12%
Ldl/hdl Ratio Decreased: 4 people, 12.12%
Cardiac Failure Chronic: 4 people, 12.12%
Cardiac Failure: 4 people, 12.12%

* Approximation only. Some reports may have incomplete information.

Do you take Vimpat and have Temporal memory loss?

- Check whether Temporal memory loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies:

Vimpat and Temporal memory loss

How the study uses the data?

The study is based on (applicable) gender, age, lacosamide (the active ingredients of Vimpat) and Vimpat (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.